Amgen/Allergan Target Lucrative Avastin Market With Another Biosimilar Filing
Executive Summary
Amgen and Allergan have filed an EU marketing authorization application for their biosimilar version of Roche’s monoclonal antibody product for cancer, Avastin (bevacizumab). In doing so, they join a growing number of biosimilars awaiting approval by the European authorities.
You may also be interested in...
Amgen’s Biosimilar Adalimumab First To EU Nod But No Launch
Amgen’s biosimilar version of the anti-TNF adalimumab has become the first to receive an EU positive opinion but the company has no plans to launch the product this year.
Amgen’s Biosimilar Adalimumab First To EU Nod But No Launch
Amgen’s biosimilar version of the anti-TNF adalimumab has become the first to receive an EU positive opinion but the company has no plans to launch the product this year.
Blockbuster Competitors Figure Large Among Biosimilars Under Review in EU
Amgen’s first biosimilar – a competitor to AbbVie’s Humira – and three would-be competitors to Amgen’s own Neulasta are among the 17 biosimilar products that are under evaluation at the European Medicines Agency.